See more : Gladstone Investment Corporation (0IVR.L) Income Statement Analysis – Financial Results
Complete financial analysis of The Beauty Health Company (SKIN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of The Beauty Health Company, a leading company in the Household & Personal Products industry within the Consumer Defensive sector.
- Weatherford International plc (WFRD) Income Statement Analysis – Financial Results
- Polytec Holding AG (P4N.DE) Income Statement Analysis – Financial Results
- Albemarle Corporation (0HC7.L) Income Statement Analysis – Financial Results
- Vericel Corporation (VCEL) Income Statement Analysis – Financial Results
- IM Cannabis Corp. (IMCC.CN) Income Statement Analysis – Financial Results
The Beauty Health Company (SKIN)
Industry: Household & Personal Products
Sector: Consumer Defensive
Website: https://www.beautyhealth.com
About The Beauty Health Company
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, peel, exfoliate, extract, infuse, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a HydraFacial Delivery System designed to elevate every part of the treatment and connects providers to the consumer's preferences to create a more personalized experience; HydraFacial Nation App, an app that allows consumers to learn about their skin health, discover treatment options, and track their treatments over time; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 397.99M | 365.88M | 260.09M | 119.09M | 166.62M | 112.31M |
| Cost of Revenue | 242.88M | 115.54M | 78.26M | 51.89M | 60.11M | 39.34M |
| Gross Profit | 155.11M | 250.34M | 181.83M | 67.20M | 106.51M | 72.98M |
| Gross Profit Ratio | 38.97% | 68.42% | 69.91% | 56.43% | 63.92% | 64.98% |
| Research & Development | 10.10M | 8.44M | 8.20M | 3.41M | 4.61M | 2.40M |
| General & Administrative | 131.43M | 106.10M | 98.69M | 30.65M | 26.66M | 17.77M |
| Selling & Marketing | 144.50M | 160.08M | 111.58M | 50.32M | 61.77M | 42.74M |
| SG&A | 275.93M | 266.18M | 210.27M | 80.97M | 88.44M | 60.51M |
| Other Expenses | 0.00 | -1.65M | -51.55M | -47.00K | 535.00K | -9.00K |
| Operating Expenses | 286.03M | 274.62M | 218.47M | 84.38M | 93.05M | 62.92M |
| Cost & Expenses | 528.91M | 390.16M | 296.73M | 136.27M | 153.16M | 102.25M |
| Interest Income | 23.17M | 9.18M | 39.00K | 21.28M | 17.09M | 0.00 |
| Interest Expense | 13.65M | 13.39M | 11.78M | 21.28M | 17.09M | 10.05M |
| Depreciation & Amortization | 34.68M | 22.02M | 21.14M | 14.40M | 13.74M | 11.50M |
| EBITDA | -56.00M | 80.75M | -344.44M | -2.81M | 27.90M | 21.56M |
| EBITDA Ratio | -14.07% | -4.58% | -33.91% | -2.37% | 16.73% | 19.19% |
| Operating Income | -130.92M | -24.28M | -36.64M | -17.18M | 13.46M | 10.06M |
| Operating Income Ratio | -32.89% | -6.64% | -14.09% | -14.43% | 8.08% | 8.96% |
| Total Other Income/Expenses | 29.03M | 71.18M | -337.42M | -21.30M | -16.40M | -10.05M |
| Income Before Tax | -101.89M | 45.03M | -377.35M | -38.48M | -2.94M | 10.00K |
| Income Before Tax Ratio | -25.60% | 12.31% | -145.09% | -32.31% | -1.76% | 0.01% |
| Income Tax Expense | -1.77M | 648.00K | -2.24M | -9.31M | -1.30M | 327.00K |
| Net Income | -100.12M | 44.22M | -375.11M | -29.18M | -1.64M | -317.00K |
| Net Income Ratio | -25.16% | 12.09% | -144.22% | -24.50% | -0.98% | -0.28% |
| EPS | -0.76 | 0.30 | -3.67 | -0.85 | -0.05 | 0.00 |
| EPS Diluted | -0.76 | -0.23 | -3.67 | -0.85 | -0.05 | 0.00 |
| Weighted Avg Shares Out | 131.68M | 147.55M | 102.11M | 34.29M | 32.14M | 125.40M |
| Weighted Avg Shares Out (Dil) | 131.68M | 148.51M | 102.11M | 34.29M | 32.14M | 125.40M |
Glancy Prongay & Murray LLP Announces Investigation of The Beauty Health Company (SKIN) f/k/a Vesper Healthcare Acquisition Corp.
Beauty Health (SKIN) International Revenue Performance Explored
The Beauty Health Company (SKIN) Q3 2024 Earnings Call Transcript
The Beauty Health Company (SKIN) Reports Q3 Loss, Tops Revenue Estimates
BeautyHealth to Report Third Quarter 2024 Financial Results on November 12, 2024
Hydrafacial Announces Video Poster Abstract Presentation at the 2024 American Society for Dermatologic Surgery's Annual Meeting (ASDS): Hydrafacial enhances the outcomes of non-ablative laser and IPL treatments
The Beauty Health Company Strengthens Commercial Leadership Team with Chief Revenue Officer and Chief Marketing Officer Appointments
e.l.f. SKIN Is Salvation to Skincare Shame in Satirical “Divine Skintervention” Campaign
The Beauty Health Company Q2 2024 Earnings: Will It Ever Be Profitable?
The Beauty Health Company (SKIN) Q2 2024 Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports